What is the expected growth forecast for the next five years?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Moderate to Severe Plaque Psoriasis Medications market?

Increasing prevalence and rising awareness of plaque psoriasis treatments drive market growth.

What are the major challenges facing the Moderate to Severe Plaque Psoriasis Medications market?

High treatment costs and limited access to medications in developing regions hinder growth.

Which regions are the leaders in the Moderate to Severe Plaque Psoriasis Medications market?

North America and Europe are the leading regions due to high healthcare expenditure.

Who are the top companies in the Moderate to Severe Plaque Psoriasis Medications market?

Key players include Johnson & Johnson, Pfizer, and Eli Lilly, offering innovative therapies.

What future opportunities exist in the Moderate to Severe Plaque Psoriasis Medications market?

Emerging markets and biosimilar drugs offer significant growth opportunities for manufacturers.

How will technology impact the Moderate to Severe Plaque Psoriasis Medications market?

Advances in biotechnology and digital health will improve treatment outcomes and patient engagement.

What is the current regulatory landscape for the Moderate to Severe Plaque Psoriasis Medications market?

Stringent regulations and safety protocols govern the market, ensuring efficacy and safety.

Moderate to Severe Plaque Psoriasis Medications Industry Size, Share & Growth Forecast 2033

Moderate to Severe Plaque Psoriasis Medications by Application (Hospital Clinic, Pharmacy, Online Shopping Mall), by Types (Injection, Oral, Topical Cream), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $15.3 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $15.3 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Moderate to Severe Plaque Psoriasis Medications Market Overview

The Moderate to Severe Plaque Psoriasis Medications market refers to the industry focused on developing and marketing treatments for moderate to severe plaque psoriasis, a chronic skin condition. The Moderate to Severe Plaque Psoriasis Medications market size is estimated to be approximately $21.5 billion in 2025. As the global Moderate to Severe Plaque Psoriasis Medications market continues to evolve, it is expected to witness a significant growth outlook driven by increasing prevalence, advances in treatment options, and rising awareness about the condition. The market forecast suggests a promising future, with the industry expansion expected to be fueled by emerging therapies and technologies. The scope of this market encompasses various treatment options, including biologics, small molecules, and topical therapies, catering to diverse patient needs and preferences.

Loading chart…

The Moderate to Severe Plaque Psoriasis Medications market is expected to grow at a CAGR of around 8% from 2026 to 2033, driven by macro drivers such as increasing disease prevalence, advancements in treatment options, and rising patient awareness. Key forces shaping the industry include technology shifts, such as the development of novel biologics and small molecules, regulations, such as stringent safety and efficacy standards, and consumer behavior, with patients increasingly seeking effective and convenient treatment options. The largest region for this market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare expenditure and growing patient awareness. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, challenges, and opportunities to make strategic decisions and drive business growth.

Report Overview

Report Attribute	Details
Market size value in 2025	15.30 million
Revenue forecast in 2033	30.94 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Biotech; Abbvie; Sandoz; Amgen; Eli Lilly; Novartis; Sun Pharmaceutical Industries; UCB, Inc; Dermavant Sciences; GSK
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Moderate to Severe Plaque Psoriasis Medications market is poised for significant growth, driven by increasing prevalence and awareness of the condition. Key drivers, restraints, opportunities, and challenges are shaping the market landscape.

Growth Drivers2 items

Advances in biologic therapies and small molecule treatments are expanding treatment options, contributing to the Moderate to Severe Plaque Psoriasis Medications market size and growth forecast.

Government initiatives and rising healthcare expenditure in emerging economies are improving access to Moderately to Severe Plaque Psoriasis Medications, further fueling market expansion.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Moderate to Severe Plaque Psoriasis Medications market, potentially hindering growth.

Side effects and risks associated with existing treatments are leading to patient reluctance, affecting demand and Moderate to Severe Plaque Psoriasis Medications market size.

Opportunities2 items

Personalized medicine and targeted therapies offer significant opportunities for growth in the Moderate to Severe Plaque Psoriasis Medications market, with potential for improved efficacy and patient outcomes.

Increasing adoption of biosimilars and generic versions of biologic treatments can enhance accessibility and affordability, driving Moderate to Severe Plaque Psoriasis Medications market expansion in price-sensitive regions.

Challenges2 items

The patent expiration of key biologic treatments is expected to lead to increased competition from biosimilars, affecting revenue and growth forecast in the Moderate to Severe Plaque Psoriasis Medications market.

Variability in reimbursement policies and pricing regulations across regions poses a significant challenge for manufacturers, impacting the Moderate to Severe Plaque Psoriasis Medications market size and profitability.

Market Segmentation

Loading chart…

The Moderate to Severe Plaque Psoriasis Medications market can be segmented based on Application, which includes hospital, clinic, and home care. The hospital segment holds the largest share due to the high cost of treatments and the need for close monitoring. Clinic settings also contribute significantly as they offer specialized care. Home care is the fastest-growing segment due to the increasing preference for self-administered medications.

Another crucial segmentation category in the Moderate to Severe Plaque Psoriasis Medications market is Types, which encompasses subtypes such as biologics, oral medications, and topical treatments. Biologics dominate the market due to their high efficacy and targeted mechanism of action. Oral medications are preferred for their ease of administration, while topical treatments are commonly used for mild to moderate cases. Understanding these segments is vital for Moderate to Severe Plaque Psoriasis Medications segmentation and market taxonomy.

Moderate to Severe Plaque Psoriasis Medications Segmentation Breakdown8 items

Application

Hospital Clinic

Pharmacy

Online Shopping Mall

Types

Injection

Oral

Topical Cream

Regional Insights

Loading chart…

The Moderate to Severe Plaque Psoriasis Medications market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of biologic therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a high prevalence of plaque psoriasis, increased awareness about available treatments, and a well-established ecosystem. In Europe, drivers include a strong pharmaceutical industry, favorable reimbursement policies, and a large patient population. Asia Pacific is driven by a growing middle-class population, increasing infrastructure development, and rising demand for innovative therapies. Latin America and Middle East & Africa are expected to be driven by improving demographics, expanding healthcare access, and growing economic stability.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by emerging markets such as China and India. The Moderate to Severe Plaque Psoriasis Medications market is expected to witness significant growth in the coming years, with key factors such as adoption, policies, investments, demographics, infrastructure, and ecosystem maturity playing a crucial role in shaping the market landscape.

Competitive Landscape

The Moderate to Severe Plaque Psoriasis Medications competitive landscape is moderately consolidated, with a mix of global players and local companies driving the market. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is characterized by high competition, with companies focusing on differentiation through product portfolios and strategic partnerships. The Moderate to Severe Plaque Psoriasis Medications competitive landscape is shaped by these factors, leading to a dynamic and evolving market.

Companies in this market employ various strategies to stay competitive, including mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To overcome these challenges, companies must develop effective strategies to maintain their market position.

Janssen Biotech: regional expansion

Abbvie: innovation pipeline

Sandoz: local manufacturing

Amgen: premium pricing

Eli Lilly: vertical integration

Novartis: OEM tie-ups

Key Moderate to Severe Plaque Psoriasis Medications Companies10 items

Janssen Biotech

Abbvie

Sandoz

Amgen

Eli Lilly

Novartis

Sun Pharmaceutical Industries

UCB, Inc

Dermavant Sciences

GSK

Market Ecosystem

The Moderate to Severe Plaque Psoriasis Medications ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. The ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into finished products; and downstream, where products are distributed and consumed. Value is created and captured at each stage, with technology providers and manufacturers driving innovation, and distributors and end users influencing demand.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce finished medications

Technology providers — develop new formulations and delivery systems

Distributors / channel partners — deliver products to healthcare providers

Service providers / after-sales — offer patient support and education

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — prescribe and administer treatments

In the Moderate to Severe Plaque Psoriasis Medications ecosystem, control points are largely held by regulators and manufacturers, who influence adoption through approvals and product development. Dependency risks arise from input constraints, such as shortages of active pharmaceutical ingredients, and standards, such as those governing clinical trials. Switching costs are high due to the complex nature of these medications, and partnerships between manufacturers and distributors are critical to ensuring timely delivery to end users. As the ecosystem differs by region, with varying regulatory frameworks and healthcare systems, a nuanced understanding of these dynamics is essential for effective value chain analysis.

Recent Industry Insights

The Moderate to Severe Plaque Psoriasis Medications industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated the development of innovative treatments. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and strengthen their positions in the market. Furthermore, several product launches have introduced new therapies, including biologics and small molecules, which have shown promising efficacy and safety profiles.

In addition to these advancements, regulatory changes have played a crucial role in shaping the industry landscape. The FDA has approved several new treatments, while also implementing stricter guidelines for the development and approval of psoriasis medications. The Moderate to Severe Plaque Psoriasis Medications industry trends are also being influenced by shifting consumer preferences, with patients increasingly seeking more effective and convenient treatment options. As a result, companies are focusing on developing patient-centric therapies that address the unique needs of this population.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Moderate to Severe Plaque Psoriasis Medications market. The market attractiveness of this sector is significant, driven by an increasing prevalence of psoriasis and a growing demand for effective treatments. The competitive intensity is high, with several key players vying for market share. Looking ahead, the long-term Moderate to Severe Plaque Psoriasis Medications market outlook is promising, with a strong innovation landscape and a growing demand-supply balance.

Key risk factors, including regulatory changes and patent expirations, may impact the market. However, the overall demand for effective treatments is expected to drive growth. Decision-makers should consider these factors when navigating the Moderate to Severe Plaque Psoriasis Medications market.

11 items

1. Executive Summary

2. Moderate to Severe Plaque Psoriasis Medications Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Moderate to Severe Plaque Psoriasis Medications Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Moderate to Severe Plaque Psoriasis Medications Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Clinic

6.1.2. Pharmacy

6.1.3. Online Shopping Mall

6.2. Global Moderate to Severe Plaque Psoriasis Medications Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Injection

6.2.2. Oral

6.2.3. Topical Cream

6.3. Global Moderate to Severe Plaque Psoriasis Medications Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Moderate to Severe Plaque Psoriasis Medications Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Moderate to Severe Plaque Psoriasis Medications Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Moderate to Severe Plaque Psoriasis Medications Market Competition by Key Manufacturers

8.1. Global Moderate to Severe Plaque Psoriasis Medications Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Moderate to Severe Plaque Psoriasis Medications: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Janssen Biotech

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbvie

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sandoz

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amgen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eli Lilly

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sun Pharmaceutical Industries

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. UCB, Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Dermavant Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. GSK

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Moderate to Severe Plaque Psoriasis Medications Market

Figure 4: Global Moderate to Severe Plaque Psoriasis Medications Market: Drivers

Figure 5: Global Moderate to Severe Plaque Psoriasis Medications Market: Challenges

Figure 6: Global Moderate to Severe Plaque Psoriasis Medications Market: Trends

Figure 7: Global Moderate to Severe Plaque Psoriasis Medications Market: Opportunity

Figure 8: Global Moderate to Severe Plaque Psoriasis Medications Market: Restraint

Figure 9: Global Moderate to Severe Plaque Psoriasis Medications Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Moderate to Severe Plaque Psoriasis Medications Market Value (USD Million) By Region

Figure 15: Global Moderate to Severe Plaque Psoriasis Medications Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Moderate to Severe Plaque Psoriasis Medications Market Value (USD Million) By Region

Figure 23: Global Moderate to Severe Plaque Psoriasis Medications Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Moderate to Severe Plaque Psoriasis Medications Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Moderate to Severe Plaque Psoriasis Medications Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Moderate to Severe Plaque Psoriasis Medications Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Moderate to Severe Plaque Psoriasis Medications Market Value (USD Million) By Region

Table 10: Global Moderate to Severe Plaque Psoriasis Medications Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Moderate to Severe Plaque Psoriasis Medications Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Moderate to Severe Plaque Psoriasis Medications Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Moderate to Severe Plaque Psoriasis Medications Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Janssen Biotech Basic Information And Sales Area

Table 31: Janssen Biotech. Products Portfolio

Table 32: Abbvie Basic Information And Sales Area

Table 33: Abbvie. Products Portfolio

Table 34: Sandoz Basic Information And Sales Area

Table 35: Sandoz. Products Portfolio

Table 36: Amgen Basic Information And Sales Area

Table 37: Amgen. Products Portfolio

Table 38: Eli Lilly Basic Information And Sales Area

Table 39: Eli Lilly. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 43: Sun Pharmaceutical Industries. Products Portfolio

Table 44: UCB, Inc Basic Information And Sales Area

Table 45: UCB, Inc. Products Portfolio

Table 46: Dermavant Sciences Basic Information And Sales Area

Table 47: Dermavant Sciences. Products Portfolio

Table 48: GSK Basic Information And Sales Area

Table 49: GSK. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Moderate to Severe Plaque Psoriasis Medications Market Value (USD Million) By Region

Table 55: Global Moderate to Severe Plaque Psoriasis Medications Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Moderate to Severe Plaque Psoriasis Medications Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	15.30 million
Revenue forecast in 2033	30.94 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Biotech; Abbvie; Sandoz; Amgen; Eli Lilly; Novartis; Sun Pharmaceutical Industries; UCB, Inc; Dermavant Sciences; GSK
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in biologic therapies and small molecule treatments are expanding treatment options, contributing to the Moderate to Severe Plaque Psoriasis Medications market size and growth forecast.

Government initiatives and rising healthcare expenditure in emerging economies are improving access to Moderately to Severe Plaque Psoriasis Medications, further fueling market expansion.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Moderate to Severe Plaque Psoriasis Medications market, potentially hindering growth.

Side effects and risks associated with existing treatments are leading to patient reluctance, affecting demand and Moderate to Severe Plaque Psoriasis Medications market size.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Moderate to Severe Plaque Psoriasis Medications Segmentation Breakdown8 items

Application

Hospital Clinic

Pharmacy

Online Shopping Mall

Types

Injection

Oral

Topical Cream

Regional Insights

Loading chart…

Competitive Landscape

Janssen Biotech: regional expansion

Abbvie: innovation pipeline

Sandoz: local manufacturing

Amgen: premium pricing

Eli Lilly: vertical integration

Novartis: OEM tie-ups

Key Moderate to Severe Plaque Psoriasis Medications Companies10 items

Janssen Biotech

Abbvie

Sandoz

Amgen

Eli Lilly

Novartis

Sun Pharmaceutical Industries

UCB, Inc

Dermavant Sciences

GSK

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce finished medications

Technology providers — develop new formulations and delivery systems

Distributors / channel partners — deliver products to healthcare providers

Service providers / after-sales — offer patient support and education

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — prescribe and administer treatments

Recent Industry Insights

Analyst Overview

Table of Contents